Working… Menu

CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03118180
Recruitment Status : Unknown
Verified April 2017 by He Huang, Zhejiang University.
Recruitment status was:  Recruiting
First Posted : April 18, 2017
Last Update Posted : April 18, 2017
Innovative Cellular Therapeutics Co., Ltd.
Information provided by (Responsible Party):
He Huang, Zhejiang University

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : December 31, 2020